Canaccord Genuity Group Forecasts Strong Price Appreciation for Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics (NASDAQ:STOK) had its price objective boosted by equities researchers at Canaccord Genuity Group from $36.00 to $60.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target points to a potential upside of 79.10% from the stock’s previous close.

Other analysts also recently issued research reports about the company. Guggenheim assumed coverage on Stoke Therapeutics in a research note on Thursday, February 5th. They set a “buy” rating and a $60.00 target price for the company. Wolfe Research began coverage on Stoke Therapeutics in a research report on Monday, February 23rd. They issued an “outperform” rating and a $40.00 price target on the stock. Chardan Capital reiterated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday. HC Wainwright raised their price objective on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Finally, Loop Capital set a $35.00 target price on shares of Stoke Therapeutics in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $41.83.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK traded up $0.31 during midday trading on Friday, hitting $33.50. The company’s stock had a trading volume of 2,012,441 shares, compared to its average volume of 777,802. The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of 50.00 and a beta of 1.07. The stock’s 50 day simple moving average is $32.60 and its 200 day simple moving average is $29.93. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $40.22.

Insider Activity

In other Stoke Therapeutics news, insider Barry Ticho sold 6,686 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $209,539.24. Following the completion of the sale, the insider owned 40,798 shares in the company, valued at approximately $1,278,609.32. This trade represents a 14.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Adrian R. Krainer sold 33,243 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $39.74, for a total value of $1,321,076.82. Following the sale, the director directly owned 283,302 shares in the company, valued at $11,258,421.48. The trade was a 10.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 69,699 shares of company stock valued at $2,526,714. Corporate insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC boosted its stake in shares of Stoke Therapeutics by 1.2% in the 4th quarter. AQR Capital Management LLC now owns 29,467 shares of the company’s stock valued at $935,000 after purchasing an additional 354 shares in the last quarter. Strs Ohio increased its position in shares of Stoke Therapeutics by 9.4% during the 4th quarter. Strs Ohio now owns 7,000 shares of the company’s stock worth $222,000 after purchasing an additional 600 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Stoke Therapeutics by 31.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock valued at $88,000 after purchasing an additional 658 shares during the last quarter. Generali Investments Management Co LLC lifted its holdings in Stoke Therapeutics by 41.0% during the 4th quarter. Generali Investments Management Co LLC now owns 2,471 shares of the company’s stock valued at $78,000 after purchasing an additional 718 shares during the last quarter. Finally, Kestra Advisory Services LLC acquired a new position in Stoke Therapeutics in the fourth quarter valued at about $26,000.

Key Headlines Impacting Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Several research firms reaffirmed or raised bullish views and price targets on STOK, signaling analyst-driven demand and upside potential; Chardan reiterated a “Buy” rating. Chardan Capital Reiterates “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)
• Positive Sentiment: BTIG, Wedbush and Needham published bullish notes or raised targets (BTIG reaffirmed Buy with a $39 target; Wedbush boosted its target to $38), which can attract momentum buyers and support the rally. BTIG Research reaffirmation (Benzinga)
• Positive Sentiment: Clinical coverage emphasized STK‑001’s potential beyond seizure control—reporting that the program aims to reverse developmental loss in Dravet syndrome, a narrative that supports longer‑term valuation. Beyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Market analysis pieces examined a recent sharp pullback and drivers behind it—useful context for traders but not a new company-specific catalyst. Stoke Therapeutics (NASDAQ:STOK) What Triggered This Sudden Drop?
• Negative Sentiment: Significant insider selling was disclosed March 17–19 across multiple executives (CFO, General Counsel and others), with double‑digit percentage trims in positions—this cluster of sales can weigh on sentiment and invites investor caution; representative SEC filing. SEC Form 4 (Jonathan Allan)

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.